CTLA4 and liver cancer: In order to identify novel immune biomarkers from the TCGA-LIHC and examine associated expression with established immune biomarkers for T cell activation with an immune checkpoint inhibitor in liver cancer, this study examined PDCD1, CTLA4, HAVCR2, and LAG3.